亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Abstract 5706: ImmunoPROFILE: A prospective implementation of clinically validated, quantitative immune cell profiling test identifies tumor-infiltrating CD8+ and PD-1+ cell densities as prognostic biomarkers across a 2,023 patient pan-cancer cohort treated with different therapies

医学 生物标志物 FOXP3型 CD8型 肿瘤科 肿瘤浸润淋巴细胞 人口 一致性 比例危险模型 免疫系统 内科学 病理 免疫学 生物 生物化学 环境卫生
作者
James Lindsay,Bijaya Sharma,Kristen D. Felt,Anita Giobbie‐Hurder,Ian Dryg,Jason L. Weirather,Jennifer Altreuter,Tali Mazor,Priti Kumari,Joao Alessi,Ajit J. Nirmal,Michael P. Manos,Ananth R. Kumar,William Lotter,Ethan Cerami,B. Johnson,Neil I. Lindeman,Lynette M. Sholl,Jonathan A. Nowak,Scott J. Rodig
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:83 (7_Supplement): 5706-5706
标识
DOI:10.1158/1538-7445.am2023-5706
摘要

Abstract Tumor-infiltrating lymphocyte (TIL) density has been identified as a prognostic and predictive biomarker in select tumors treated with defined therapies. These observations suggest that TILs may be general markers of patient outcomes, but evidence in support of this hypothesis has been limited by small cohorts. We validated ImmunoPROFILE, a multiplexed immunofluorescence (MIF)-based assay coupled with machine-learning-based image analysis, to identify and quantify tumor cells (cytokeratin, PAX5, PAX8, SOX10), T cells (CD8), T-regulatory cells (FOXP3), exhausted cells (PD-1) and immunosuppressive tumor and immune cells (PD-L1). We applied the MIF panel to specimens from patients collected prospectively over three years and analyzed 2,023 cases across 27 tumor types. The association between biomarkers and overall survival (OS) was investigated using Cox models controlling for patient risk factors such as cancer type, metastatic vs. primary disease, age, and gender. Multivariable biomarker selection was based on likelihood ratios. The assay was highly robust (success rate 97%), reproducible (inter-scanning and intra-staining density controls within 1 SD, inter-staining PD-L1 scores ≤11% CV), and operator-independent (R2 >0.7 to >0.9 for each biomarker and 95% concordance in PD-L1 score-based interpretation between technicians). From whole slide images, a total of 11,932 individual regions of interest were analyzed across the cohort, resulting in >50 million spatially-resolved single cells which were summarized into cell population densities and PD-L1 scores. High densities of CD8+ (>64/mm2, p<0.0001), PD-1+ (>50/mm2, p<0.0001), and FOXP3+ (>30/mm2, p<0.0001) T cells were associated with longer overall survival (OS) irrespective of therapy and across all cancer types. PD-L1 metrics were not associated with OS (p=0.43). Compared to patients with low densities of CD8+ and PD-1+ cells, high densities of at least one of these cell types had better OS (Both high, HR: 0.49, 95% CI: 0.41 - 0.59; CD8+ high, HR: 0.63, (0.48 - 0.82); PD-1+ high, HR: 0.71, (0.54 - 0.93)). The results were consistent in the subset of patients (N=1572) who did not receive immunotherapy (IO). In patients who received IO therapy (N=451), only PD-1+ T-cell density associated with OS (HR: 0.48, (0.36 - 0.65)). To our knowledge, this is the first enterprise-level immune biomarker assay using multiplexed staining, digital imaging, and machine learning to be applied in a prospective manner to clinical specimens at scale. We found that select immune cell densities are prognostic across cancer types and therapies and demonstrated that quantification of multiple cell populations yields better prognostic power than single marker analyses. Citation Format: James Lindsay, Bijaya Sharma, Kristen D. Felt, Anita Giobbie-Hurder, Ian Dryg, Jason L. Weirather, Jennifer Altreuter, Tali Mazor, Priti Kumari, Joao V. Alessi, Ajit J. Nirmal, Michael P. Manos, Ananth R. Kumar, William Lotter, Ethan Cerami, Burce E. Johnson, Neil I. Lindeman, Lynette M. Sholl, Jonathan A. Nowak, Scott J. Rodig. ImmunoPROFILE: A prospective implementation of clinically validated, quantitative immune cell profiling test identifies tumor-infiltrating CD8+ and PD-1+ cell densities as prognostic biomarkers across a 2,023 patient pan-cancer cohort treated with different therapies. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 5706.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
7秒前
红橙黄绿蓝靛紫111完成签到,获得积分10
11秒前
cy0824完成签到 ,获得积分10
15秒前
yyy完成签到 ,获得积分10
23秒前
SciGPT应助科研通管家采纳,获得10
38秒前
失眠奥特曼完成签到,获得积分10
51秒前
51秒前
李李发布了新的文献求助10
1分钟前
李李完成签到,获得积分20
1分钟前
刘宇童完成签到,获得积分10
1分钟前
1分钟前
Jasper应助李李采纳,获得10
1分钟前
chenting完成签到 ,获得积分10
2分钟前
小付完成签到,获得积分10
2分钟前
NexusExplorer应助科研通管家采纳,获得10
2分钟前
烟消云散完成签到,获得积分10
2分钟前
汉堡包应助梦梦采纳,获得10
2分钟前
2分钟前
Orange应助reerwt采纳,获得10
3分钟前
annis完成签到,获得积分10
3分钟前
3分钟前
含蓄绿竹完成签到 ,获得积分10
3分钟前
3分钟前
reerwt发布了新的文献求助10
3分钟前
Liufgui应助sss采纳,获得10
4分钟前
梦梦完成签到,获得积分10
4分钟前
4分钟前
reerwt完成签到,获得积分20
4分钟前
4分钟前
陈元元K完成签到,获得积分10
4分钟前
英俊的铭应助科研通管家采纳,获得10
4分钟前
小二郎应助科研通管家采纳,获得10
4分钟前
4分钟前
梦梦发布了新的文献求助10
4分钟前
4分钟前
caca完成签到,获得积分0
4分钟前
科研通AI2S应助YYYCCCCC采纳,获得10
5分钟前
海鸥别叫了完成签到 ,获得积分10
6分钟前
云霞完成签到 ,获得积分10
6分钟前
朴素的山蝶完成签到 ,获得积分10
6分钟前
高分求助中
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3990045
求助须知:如何正确求助?哪些是违规求助? 3532108
关于积分的说明 11256354
捐赠科研通 3270943
什么是DOI,文献DOI怎么找? 1805146
邀请新用户注册赠送积分活动 882270
科研通“疑难数据库(出版商)”最低求助积分说明 809228